title: Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
abstract: OBJECTIVE
  To study the expression of p53, MDM2, and p14 ARF in the highly, moderately and low differentiated endometrial adenocarcinomas, compared to hyperplasia.
  
  
  METHODS
  Surgical material and the scrapes of endometrial cancer, glandular and atypical hyperplasia patients. Expression of 53, MDM2 and p14 ARF was evaluated by immunohistochemical method using respective monoclonal antibodies.
  
  
  RESULTS
  High p53 expression level is accompanied by decreased level of MDM2 expression in endometrial cancers. On contrary, in endometrial hyperplasia, there was clear connection between the expression levels of p53 and MDM2. We hypothesize that the high p53 and low MDM2 levels in endometrial cancers could arise due to the inhibition of transcriptional activity of p53 by its binding to estrogen receptors.
  
  
  CONCLUSIONS
  High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma.
authors.affiliation: RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine. lubov@onconet.kiev.ua
authors.forename: L G
authors.initials: LG
authors.lastname: Buchynska
authors.forename: I P
authors.initials: IP
authors.lastname: Nesina
authors.forename: E V
authors.initials: EV
authors.lastname: Kashuba
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D004714:Endometrial Hyperplasia / Q000378:metabolism* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D008875:Middle Aged; D011230:Precancerous Conditions / Q000378:metabolism / Q000473:pathology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000096:biosynthesis*; D025803:Tumor Suppressor Protein p14ARF / Q000096:biosynthesis*; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D025803:Tumor Suppressor Protein p14ARF; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2